证券代码：300937 证券简称：药易购 公告编号：2025-048 四川合纵药易购医药股份有限公司 关于控股股东、实际控制人协议转让部分公司股份 暨权益变动的提示性公告 李燕飞女士与甘孟先生保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 近日，四川合纵药易购医药股份有限公司（以下简称"公司"）控股股东、 实际控制人李燕飞女士与境内自然人甘孟先生签署了《股份转让协议》（以下简 称"转让协议"），约定通过协议转让方式拟转让李燕飞女士持有的公司 500 万股无限售流通股股份（以下简称"标的股份"）给受让方，占公司总股本 5.23%。 本次股份转让价格为 24.00 元/股，交易总价为 12,000.00 万元。本次股份转 让价格系根据转让协议签署之日前一交易日转让股份二级市场收盘价为定价基 准，经双方协商一致确定，符合《上市公司收购管理办法》《深圳证券交易所上 市公司股份协议转让业务办理指引》等相关规定。 本次协议转让前，李燕飞女士及其一致行动人持有公司股份 42,071,000 股， 占公司总 ...

上市公司名称：四川合纵药易购医药股份有限公司 信息披露义务人：甘孟 住所及通讯地址：浙江省杭州市 股份变动性质：股份增加（协议转让） 签署日期：2025年11月10日 1 股票上市地点：深圳证券交易所 股票简称：药易购 股票代码：300937 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司收购管理办法》《证券期货法律适用意见第19号——<上市 公司收购管理办法>第十三条、第十四条的适用意见》《公开发行证券的公司 信息披露内容与格式准则第15号——权益变动报告书》及其他相关法律、法规 和部门规章的有关规定编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《证券期 货法律适用意见第19号——<上市公司收购管理办法>第十三条、第十四条的 适用意见》和《公开发行证券的公司信息披露内容与格式准则第15号——权益 变动报告书》的规定，本报告书已全面披露信息披露义务人在四川合纵药易购 医药股份有限公司中拥有权益的股份变动情况。截至本报告书签署日，除本报告 书披露的持股信息外，上述信息披露义务人没有通过任何其他方 ...

Shareholder Reduction Plans - Zhongjing Technology's shareholder Longi Green Energy plans to reduce holdings by no more than 3.8764 million shares [1] - Guobo Electronics' shareholder China Electronics Technology Group plans to reduce holdings by no more than 2.00% [1] - Hongbai New Materials' shareholder Xinyu Baolong plans to reduce holdings by no more than 19.5 million shares [1] - Founder Securities' shareholder China Cinda plans to reduce holdings by no more than 82.321 million shares [1] - Ningbo Zhongbai's shareholder Zhang Jiangbo plans to reduce holdings by no more than 1% [1] - Suli Co., Ltd.'s shareholder Gusheng Investment plans to reduce holdings by no more than 900,000 shares [1] - Ruihua Tai's shareholder Hangke New Century plans to reduce holdings by no more than 180,000 shares [1] - Shenkong's shareholder More Liangzhao plans to reduce holdings by no more than 2% [1] Other Notable Events - Yao Yigou received a tax matter notification [1] - ST Lingnan is being prosecuted for alleged collusion in bidding [1]

Mergers and Acquisitions - Shida Group plans to acquire 95% equity of Fujian Shuchan Ming Shang Technology Co., Ltd. for a cash consideration of 185 million yuan, based on an assessed value of 194 million yuan, with funding sourced from self-owned funds and bank loans [1] Shareholding Changes - China Cinda Asset Management Co., Ltd. intends to reduce its stake by no more than 1.00%, equating to approximately 82.32 million shares [2] - Shareholder Yang Zongmeng of Fudan Zhangjiang plans to reduce his holdings by no more than 1.00%, which amounts to up to 10.36 million shares [3] - Guoshou Chengda, a shareholder of Huaxi Biological, plans to reduce its stake by no more than 2.00%, totaling up to 9.63 million shares [4] - New Yu Baolong Project Investment Center (Limited Partnership) intends to reduce its holdings in Hongbai New Materials by no more than 3.00%, which is equivalent to up to 19.5 million shares [5] Legal Issues - ST Lingnan has been sued for collusion in bidding, with a court date set for October 31, 2025. The company states that this incident has not yet significantly impacted its operations [6] Tax Matters - Yaoyigou has received a tax notice requiring it to pay approximately 6.45 million yuan in corporate income tax and late fees due to not meeting the income criteria for tax incentives [7]

Core Viewpoint - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. (stock code: 300937) announced that it received a tax notification indicating that its 2024 encouraged industry revenue did not meet the 60% threshold for enjoying the Western Development income tax preferential policy, necessitating a tax correction by November 10, 2025 [1][3]. Group 1: Tax Notification and Financial Impact - The tax notification requires the company to correct its corporate income tax returns for the years 2024 to 2025, specifically for the period from January to September [1]. - The company estimates a tax payment of approximately 5.9955 million yuan and late fees of about 455,600 yuan, totaling around 6.4511 million yuan [3]. - This tax payment and late fee will be recorded in the 2025 financial results, with the exact impact on net profit to be determined by the audited financial statements for that year [3]. Group 2: Financial Performance - For the first three quarters of 2023, the company reported a revenue of 3.24 billion yuan, a year-on-year increase of 0.2% [3]. - The net profit attributable to shareholders was approximately -8.3565 million yuan, a year-on-year decline of 159.98% [3]. - The net profit after deducting non-recurring items was approximately -10.1526 million yuan, a year-on-year decrease of 208.41% [3]. - The net cash flow from operating activities was -114 million yuan, a significant drop of 397.9% year-on-year [3]. - As of September 30, 2023, the company's asset-liability ratio was 56.02%, an increase of 11.81% year-on-year, and accounts receivable stood at 433 million yuan, up 2.83% year-on-year [3]. Group 3: Market Performance - As of the close on November 4, the company's stock price decreased by 0.25%, closing at 28.09 yuan per share, with a total market capitalization of 2.687 billion yuan [4].

Core Viewpoint - The company, Yiyigou (300937.SZ), has received a tax notification indicating that its revenue from encouraged industries for 2024 does not meet the required 60% threshold to qualify for tax incentives under the Western Development policy, leading to a tax payment obligation [1] Tax Notification Details - The company was notified by the Chengdu Jinniu District Tax Bureau that it must correct its corporate income tax returns for the years 2024 and the first nine months of 2025 by November 10, 2025 [1] - The preliminary calculation indicates that the company is required to pay approximately 5.9955 million yuan in corporate income tax and about 455,600 yuan in late fees, totaling around 6.4511 million yuan [1]

Core Viewpoint - The company received a tax notification from the Chengdu Jin Niu District Tax Bureau, indicating that it must correct its corporate income tax filings for the years 2024 to September 2025, as its income from encouraged industries did not meet the required threshold for tax benefits under the Western Development policy [1] Summary by Categories Tax Notification - The company was issued a tax matter notification requiring adjustments to its corporate income tax filings for the period of 2024 to September 2025 [1] - The notification states that the company's income from encouraged industries did not reach 60% of total income, disqualifying it from the Western Development tax incentives [1] Financial Implications - The company estimates it will need to pay approximately 5.9955 million yuan in corporate income tax and about 455,600 yuan in late fees, totaling around 6.4511 million yuan [1]

证券代码：300937 证券简称：药易购 公告编号：2025-047 四川合纵药易购医药股份有限公司 关于公司收到税务事项通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于近期收到国家税 务总局成都市金牛区税务局第二税务所《税务事项通知书》（金牛税二通【2025】 102702 号），现将有关情况公告如下： 通知内容：公司 2024 年鼓励类产业收入未达到总收入 60%，不应享受西部 大开发所得税优惠政策，要求公司于 2025 年 11 月 10 日前更正 2024 年至 2025 年 1-9 月企业所得税年度及预缴纳税申报表。 二、对公司的影响及应对措施 1、对公司的影响 公司经初步测算，本次应当补缴企业所得税 599.55 万元、滞纳金约 45.56 万元（最终以实际缴纳金额为准），合计约 645.11 万元。 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述事项不属于前期会计差错，不涉及前期财务数据追溯调整。公司本 次补缴税款及滞纳金将计入 2025 年当 ...

Group 1: Robotics in Food Industry - The application of cooking robots in restaurants allows for the preparation of various dishes in just 3-5 minutes, covering eight major cuisines and enhancing operational efficiency for restaurant owners [2][4] - The "Robot + Recipe Program + Smart Kitchen Management System" model creates a win-win situation for restaurant operators, consumers, and chefs by reducing costs and ensuring fresh meals [2] - A robot bartender can accurately mix drinks by selecting ingredients and performing shaking and stirring tasks, showcasing the versatility of robotics in food service [3] Group 2: Robotics in Agriculture - Robots designed for apple picking can navigate complex environments and accurately harvest fruit, with future models targeting different heights for optimal efficiency [5] - The "Greenhouse Bumblebee" robot mimics the pollination process of bumblebees, achieving a 98% success rate in pollination while reducing costs to 30% of traditional methods [6][7] - The integration of visual recognition and multi-sensor navigation in agricultural robots enhances their functionality and effectiveness in crop management [7] Group 3: Robotics in Healthcare and Elderly Care - The rise in demand for elderly care services has led to the development of rehabilitation robots that assist patients with mobility issues, providing support and promoting muscle memory [8] - Massage therapy robots can automate the massage process, adjusting techniques based on user preferences and body data, thus improving service quality in elderly care [9] - The use of robotics in healthcare settings addresses the challenges of high service costs and low standardization, offering efficient and precise care solutions [8]

Core Insights - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. reported a steady growth in revenue and an optimized business structure in its Q3 2025 report, indicating a solid foundation for future development [1][2][3] Revenue Performance - In Q3 2025, the company achieved a revenue of 1.085 billion yuan, representing a year-on-year increase of 7.41% [1] - Cumulative revenue for the year reached 3.242 billion yuan, showing growth compared to the previous year [1] - The company demonstrated strong operational resilience amidst intensified competition in the pharmaceutical distribution industry [1] Supply Chain and Business Optimization - The company's accounts payable increased by 81.37% compared to the end of the previous year, enhancing capital efficiency and supplier collaboration [2] - Construction of new non-pharmaceutical production lines surged by 360.77%, diversifying product offerings and expanding growth points [2] Investment and Financial Performance - Long-term equity investments grew by 112.16%, with new investments in affiliated companies, expanding the business landscape in the healthcare sector [2] - Investment income saw a significant increase of 300.24% year-on-year, contributing positively to overall performance [2] Cost Management and Subsidiary Development - Despite an increase in sales expenses due to e-commerce expansion, subsidiaries showed significant profit growth, leading to a 39.38% rise in tax liabilities compared to the previous year [2] Future Outlook - The company plans to continue leveraging its pharmaceutical distribution advantages, deepen supply chain strengths, accelerate non-pharmaceutical production line development, and pursue innovative business expansion for higher quality growth [3]